Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

MDA-MB-468 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (3) Akt (2) Apoptosis (12) Aryl Hydrocarbon Receptor (1) Bcl-2 Family (1) c-Myc (1) Carbonic Anhydrase (1) CDK (10) Drug-Linker Conjugates for ADC (1) DYRK (2) Early 2 Factor (E2F) (1) Epigenetic Reader Domain (1) FAK (1) FLT3 (1) Gli (1) GSK-3 (2) Hedgehog (1) HSP (6) MELK (2) Mps1 (1) mTOR (2) NF-κB (1) Phosphoglycerate Dehydrogenase (PHGDH) (2) PI3K (1) Pim (2) PIN1 (2) Polo-like Kinase (PLK) (2) PROTACs (6) Proteasome (1) Pyroptosis (1) Reactive Oxygen Species (1) RIP kinase (2) SHP2 (1) Smo (1) Src (2) SRPK (1) STAT (3) Topoisomerase (1) TrxR (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (47) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (1)

By Targets:

ADC Cytotoxin (3)

Akt (2)

Apoptosis (12)

Aryl Hydrocarbon Receptor (1)

Bcl-2 Family (1)

c-Myc (1)

Carbonic Anhydrase (1)

CDK (10)

Drug-Linker Conjugates for ADC (1)

DYRK (2)

Early 2 Factor (E2F) (1)

Epigenetic Reader Domain (1)

FAK (1)

FLT3 (1)

Gli (1)

GSK-3 (2)

Hedgehog (1)

HSP (6)

MELK (2)

Mps1 (1)

mTOR (2)

NF-κB (1)

Phosphoglycerate Dehydrogenase (PHGDH) (2)

PI3K (1)

Pim (2)

PIN1 (2)

Polo-like Kinase (PLK) (2)

PROTACs (6)

Proteasome (1)

Pyroptosis (1)

Reactive Oxygen Species (1)

RIP kinase (2)

SHP2 (1)

Smo (1)

Src (2)

SRPK (1)

STAT (3)

Topoisomerase (1)

TrxR (1)

VEGFR (1)

γ-secretase (1)

By Research Areas:

Cancer (47)

Infection (1)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-11038B

Zelavespib hydrochloride 1 Publications Verification PU-H71 hydrochloride	HSP	Cancer
Zelavespib (PU-H71) hydrochloride is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-11038

Zelavespib 1 Publications Verification PU-H71	HSP	Cancer
Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC₅₀ of 51 nM in MDA-MB-468 cells.

HY-N8187

Eupalinolide O	Apoptosis	Cancer
Eupalinolide O is a sesquiterpene lactone with anticancer activities. Eupalinolide O induces cell apoptosis in human MDA-MB-468 breast cancer cells .

HY-11038D

Zelavespib formic 1 Publications Verification PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC₅₀ value of 51 nM for Hsp90 in MDA-MB-468 cells .

HY-158170

CDK7-IN-28	CDK	Cancer
CDK7-IN-28 (CDK7-1276) is a potent CDK7 inhibitor(IC₅₀＜5 nM). CDK7-IN-28 can inhibit proliferation of MDA-MB-468 cell line by blocking cell cycle and inhibiting DNA replication .

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

HY-101447

SI-2 EPH 116	Src Apoptosis	Cancer
SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, with IC₅₀s ranging from 3-20 nM, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg) .

HY-147670

TPB15	Hedgehog Smo Gli Apoptosis	Cancer
TPB15 is an orally active and potent Hh (Hedgehog) signaling inhibitor. TPB15 markedly induces cell cycle arrest and apoptosis in MDA-MB-468 cells. TPB15 blocks Smo (Smoothened) translocation into the cilia and reduced Smo protein and mRNA expression. TPB15 inhibits the expression of the downstream regulatory factor glioma-associated oncogene 1 (Gli1). TPB15 shows good anti-tumor activity with low toxicity .

HY-145860

PHGDH-IN-2	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-2 is a potent and NAD ⁺ competitive PHGDH inhibitor with an IC₅₀ of 5.2 µM. PHGDH-IN-2 inhibits the serine synthetic pathway in MDA-MB-468 cells. PHGDH-IN-2 inhibits the growth of PHGDH-dependent cancer cells .

HY-161456

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-155098

CNBCA	SHP2	Cancer
CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC₅₀ of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study .

HY-159576

O-Me Eribulin O-Me B1939; O-Me E7389; O-Me ER-086526	ADC Cytotoxin	Cancer
O-Me Eribulin is a derivative of Eribulin and is an ADC cytotoxin that can be used for ADC synthesis. O-Me Eribulin can inhibit the cell viability of SKBR3, MDA-MB-468, and A549 cells, with IC₅₀ values of 0.2052, 0.1827, and 0.5151 nM, respectively. O-Me Eribulin can be used for tumor research .

HY-152945

Antiproliferative agent-22	NF-κB	Cancer
Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC₅₀ values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .

HY-160598

Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol	ADC Cytotoxin Topoisomerase	Cancer
Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC₅₀ of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer .

HY-168037

PROTAC PIN1 degrader-1	PROTACs PIN1	Cancer
PROTAC PIN1 degrader-1 is a targeted PROTAC for PIN1. PROTAC PIN1 degrader-1 can degrade the PIN1 protein in MDA-MB-468 triple-negative breast cancer cells, with a DC₅₀ value of 0.018 μM. PROTAC PIN1 degrader-1 can be used for tumor research .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-151630

hCAIX-IN-16	Carbonic Anhydrase	Cancer
hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with K_{i values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .}

HY-160899A

Thailanstatin A cyclohexane diamine formic	Drug-Linker Conjugates for ADC	Cancer
Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC₅₀ is 0.33 μM), BT474 (IC₅₀ is 0.34 μM), MDA-MB-361-DYT2 (IC₅₀ is 0.88 μM) and MDA-MB-468 (IC₅₀ is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .

HY-162751

Anticancer agent 249	HSP Apoptosis	Cancer
Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC₅₀ of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC₅₀ of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .

HY-155113

PROTAC Hsp90α degrader 1	PROTACs HSP	Cancer
PROTAC Hsp90α degrader 1 (Compound X10g) is a selective PROTAC Hsp90α degrader. PROTAC Hsp90α degrader 1 can be used for breast cancer research. PROTAC Hsp90α degrader 1 inhibits the proliferation of MDA-MB-231, MDA-MB-468, MCF-7, MX-1 cells with IC₅₀s of 51.48 μM, 16.46 μM, 8.93 μM, 11.95 μM respectively .

HY-163709

PROTAC FAK degrader 2	PROTACs FAK	Cancer
PROTAC FAK degrader 2 (Compound F2) is a PROTAC degrader for focal adhesion kinase (FAK), with DC₅₀ of 27.72 and 60.1 nM, for total FAK and phosphorylated p-FAK. PROTAC FAK degrader 2 inhibits cell viability of cancer cells 4T1, MDA-MB-231, MDA-MB-468 and MDA-MB-435, with IC₅₀s of 0.73-5.84 μM. PROTAC FAK degrader 2 reverses the multidrug resistance (MDR) through inhibition of AKT and ERK signaling pathway. PROTAC FAK degrader 2 exhibits antitumor efficacy in HCT/8 xenograft mouse model. (Pink: ligand for target protein Ifebemtinib (HY-122844); Black: linker (HY-Y0681); Blue: ligand for E3 ligase Thalidomide (HY-14658))

HY-155180

FD2056	PI3K	Cancer
FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC₅₀s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC₅₀ of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC₅₀s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Cytotoxin	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-149959

Mps1-IN-6	Mps1	Cancer
Mps1-IN-6 is a potent Mps1 inhibitor with an IC₅₀ value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity .

HY-133120A

INY-03-041 trihydrochloride	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-146666

STAT3-IN-9	Apoptosis STAT	Cancer
STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase .

HY-145655

CDK7-IN-11	CDK	Cancer
CDK7-IN-11 is an orally active CDK7 inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC₅₀ value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .

HY-W338764

AHR agonist 3	Apoptosis Aryl Hydrocarbon Receptor	Cancer
AHR agonist 3 is an aryl hydrocarbon receptor (AhR) agonist, that can induces cell cycle arrest or apoptosis via activation of tumor-suppressive transcriptional programs. AHR agonist 3 inhibits triple-negative breast cancer (TNBC) stem cell growth via AhR while exhibits minimal cytotoxicity against normal human primary cells and can be used for cancer research .

HY-113831

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

HY-139361

Sulfopin 1 Publications Verification PIN1-3	PIN1	Cancer
Sulfopin (PIN1-3) is a highly selective covalent inhibitor of Pin1 with an apparent K_i of 17 nM. Sulfopin blocks Myc-driven tumors in vivo. The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate tumor suppressors .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-144318

CREB-IN-1 TFA	Epigenetic Reader Domain	Cancer
CREB-IN-1 TFA is a potent, orally active CREB inhibitor (IC₅₀=0.18 µM). CREB-IN-1 TFA inhibits breast cancer cell growth .

HY-149209

LL-K8-22	CDK STAT Early 2 Factor (E2F)	Cancer
LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC₅₀ values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research .

HY-162037

CDDD11-8	CDK FLT3	Cancer
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with K_i values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation .

HY-133120

INY-03-041	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-115589

YLT-11	Polo-like Kinase (PLK) Apoptosis	Cancer
YLT-11 is a potent, selective and orally active PLK4 inhibitor with K_d values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .

HY-122665

HTH-01-091	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .

HY-122665A

HTH-01-091 TFA	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research .

HY-103255

CFM-4	Apoptosis	Cancer
CFM-4 is a potent small molecular antagonist of CARP-1/APC-2 binding. CFM-4 prevents CARP-1 binding with APC-2, causes G₂M cell cycle arrest, and induces apoptosis with an IC₅₀ range of 10-15 μM. CFM-4 also suppresses growth of drug-resistant human breast cancer cells .

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-138071

8α-Tigloyloxyhirsutinolide 13-O-acetate 8αTGH	STAT Pyroptosis Apoptosis Reactive Oxygen Species c-Myc Bcl-2 Family TrxR	Cancer
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo .

HY-163468

SRC-3-IN-1	Src	Cancer
SRC-3-IN-1 (compound SI-10) is a steroid receptor coactivator 3 (SRC-3) inhibitor (IC₅₀=3.3 μM). SRC-3-IN-1 has good water solubility, oral bioavailability, and improved selectivity profile. SRC-3-IN-1 can be used in prostate cancer research .

HY-113825

CLK1/2-IN-1	CDK	Cancer
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-113670

CLK1/2-IN-2	CDK	Cancer
CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

HY-148104

ACSS2-IN-2	Others	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

Cat. No.	Product Name	Target	Research Area

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks